PE20211790A1 - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
PE20211790A1
PE20211790A1 PE2021000903A PE2021000903A PE20211790A1 PE 20211790 A1 PE20211790 A1 PE 20211790A1 PE 2021000903 A PE2021000903 A PE 2021000903A PE 2021000903 A PE2021000903 A PE 2021000903A PE 20211790 A1 PE20211790 A1 PE 20211790A1
Authority
PE
Peru
Prior art keywords
methyl
hydrogen
fluorine
oxetan
difluoromethyl
Prior art date
Application number
PE2021000903A
Other languages
English (en)
Spanish (es)
Inventor
Susanne Rohrig
Sebastian Essig
Pascal Ellerbrock
Sonja Anlauf
Thomas Neubauer
Alexander Hillisch
Katharina Meier
Stefan Heitmeier
Adrian Tersteegen
Martina Schafer
Jan Stampfuss
Dieter Lang
Hongping Wang
Zengqiang Zou
Xianghai Meng
Kersten Matthias Gericke
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20211790A1 publication Critical patent/PE20211790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2021000903A 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos PE20211790A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
PE20211790A1 true PE20211790A1 (es) 2021-09-09

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000903A PE20211790A1 (es) 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos

Country Status (22)

Country Link
EP (1) EP3898633A1 (pt)
JP (1) JP2022514303A (pt)
KR (1) KR20210106504A (pt)
CN (1) CN113474348A (pt)
AR (1) AR117435A1 (pt)
AU (1) AU2019407909B2 (pt)
BR (1) BR112021009435A2 (pt)
CA (1) CA3124220A1 (pt)
CL (1) CL2021001613A1 (pt)
CO (1) CO2021007908A2 (pt)
CR (1) CR20210342A (pt)
DO (1) DOP2021000128A (pt)
EA (1) EA202191764A1 (pt)
EC (1) ECSP21043895A (pt)
IL (1) IL283990A (pt)
JO (1) JOP20210161A1 (pt)
MA (1) MA54521A (pt)
MX (1) MX2021007508A (pt)
PE (1) PE20211790A1 (pt)
SG (1) SG11202104384PA (pt)
TW (1) TW202039510A (pt)
WO (1) WO2020127504A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220565T1 (hr) * 2018-03-15 2022-06-10 Bayer Aktiengesellschaft Postupak pripreme dva derivata 4-{[(2s)-2-{4-[5-klor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
CN117337170A (zh) 2021-03-09 2024-01-02 拜耳公司 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN117015535A (zh) 2021-03-09 2023-11-07 拜耳公司 (4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-5二苯庚烷-74-甲酰胺的结晶形式
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用
JP6368367B2 (ja) 2013-10-30 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
JP6517925B2 (ja) 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
CA2979937A1 (en) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate

Also Published As

Publication number Publication date
ECSP21043895A (es) 2021-07-30
TW202039510A (zh) 2020-11-01
CA3124220A1 (en) 2020-06-25
SG11202104384PA (en) 2021-05-28
IL283990A (en) 2021-07-29
DOP2021000128A (es) 2021-09-30
CL2021001613A1 (es) 2021-12-03
JOP20210161A1 (ar) 2023-01-30
AR117435A1 (es) 2021-08-04
EP3898633A1 (en) 2021-10-27
CN113474348A (zh) 2021-10-01
JP2022514303A (ja) 2022-02-10
AU2019407909A1 (en) 2021-05-27
BR112021009435A2 (pt) 2021-08-17
KR20210106504A (ko) 2021-08-30
CR20210342A (es) 2021-08-09
CO2021007908A2 (es) 2021-07-19
MX2021007508A (es) 2021-08-05
AU2019407909B2 (en) 2023-05-25
EA202191764A1 (ru) 2021-10-22
MA54521A (fr) 2022-03-30
WO2020127504A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
PE20211790A1 (es) Derivados de oxopiridina sustituidos
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2024008497A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
BR122015016965B8 (pt) 6-(aril polissubstituído)-4-aminopicolinatos, composição herbicida, e método para controle de vegetação indesejável
BR112016024443A2 (pt) composto, composição e mistura herbicida e método para o controle do crescimento da vegetação indesejada
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
PE20120689A1 (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
UA103329C2 (ru) Соли соединений-ингибиторов вич
AU2015306910A8 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
MX369345B (es) Procesos para la preparacion de analogos de oxitocina.
TW200744453A (en) Fungicidal composition containing carboxylic acid amide derivative
MX2022000154A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
JOP20210147A1 (ar) صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه